Abstract
BACKGROUND: We report preliminary results from a study on the out-of-pocket costs (cancer related costs not covered by healthcare insurance) for 57 lymphoma pts. To explore factors that influence out-of-pocket costs and QOL, cancer type, stage, time since diagnosis (Dx), treatment type (with or without rituximab), and age were evaluated.METHODS: Lymphoma pts provided information on out-of-pocket costs for 3-month periods after lymphoma Dx and completed the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) QOL measure. Monthly costs were evaluated. Direct medical costs are costs related to medications, hospital bills, and doctor visits. Direct non-medical costs are peripheral costs related to transportation, meals, and telephone calls.RESULTS: The majority of lymphoma pts were Caucasian (87%), married (63%), ≤ 55 years old (58%), and employed (40%). All pts were undergoing active treatment and had healthcare insurance coverage. 62% of pts had stage I-III lymphoma, 35% had stage IV, and 3% had unknown stage. Mean monthly total out-of-pocket costs for all 57 lymphoma pts were $818. Direct medical costs for HD pts were 3.2 and 1.4-fold higher than for INHL and ANHL pts, respectively. Direct non-medical costs were highest for ANHL. Total costs for pts < 6 months since Dx were 1.5 and 2.2-fold higher than for pts 6–12 and > 12 months since Dx, respectively. Total costs for pts undergoing treatment without rituximab were 1.5-fold higher than costs for pts with rituximab. Pts ≤ 55 years old had 1.4-fold higher costs than pts > 55 years old. QOL for pts < 6 months since Dx was greater than for pts ≥ 6 months since Dx (p-value =0.02).CONCLUSION: The mean monthly out-of-pocket costs were greatest for HD ($1,136), followed by ANHL ($847) and INHL ($447), and were driven primarily by direct medical costs. Though pts < 6 months since Dx incurred higher total costs than pts ≥ 6 months since Dx, their QOL measures were better. It is important to evaluate costs and quality of life of pts with cancer when describing the economic and psychosocial burden of cancer.Direct Medical, Direct Non-medical, and Total (Medical & Non-medical) Mean Out-of-Pocket Cost per MonthNDirect Medical Out-of-Pocket Cost ($/month)Direct Non-medical Out-of-Pocket Cost ($/month)Total Out-of-Pocket Cost ($/month)All Patients57647171818Cancer TypeHodgkin's Lymphoma169721641,136Aggressive NHL24671176847Indolent NHL17307170477Time since diagnosis<6 months288931651,0586–12 months13494215709>12 months16341146487Treatment TypeWith Rituximab36543143686Without Rituximab218252191,044Age<=55 yrs old33734188923>55 yrs old24527146673Quality of Life of Lymphoma PatientsNFACT-Lymphoma Scorep-valueAll Patients60126Cancer Type0.65Hodgkin's Lymphoma17126Aggressive NHL25128Indolent NHL18121Cancer Stage0.37I–III37124IV21126N/R2149Time since diagnosis0.02<6 months291346–12 months15116>12 months16118Age0.28<=55 yrs old35122>55 yrs old25129
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
